{"generic":"Interferon Gamma-1b","drugs":["Actimmune","Interferon Gamma-1b"],"mono":{"0":{"id":"301690-s-0","title":"Generic Names","mono":"Interferon Gamma-1b"},"1":{"id":"301690-s-1","title":"Dosing and Indications","sub":[{"id":"301690-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Chronic granulomatous disease:<\/b> BSA 0.5 m(2) or less: 1.5 mcg\/kg\/dose SUBQ 3 times a week<\/li><li><b>Chronic granulomatous disease:<\/b> BSA greater than 0.5 m(2): 50 mcg\/m(2) SUBQ 3 times a week<\/li><li><b>Osteopetrosis (Severe), Malignant:<\/b> BSA 0.5 m(2) or less: 1.5 mcg\/kg\/dose SUBQ 3 times a week<\/li><li><b>Osteopetrosis (Severe), Malignant:<\/b> BSA greater than 0.5 m(2): 50 mcg\/m(2) SUBQ 3 times a week<\/li><\/ul>"},{"id":"301690-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Chronic granulomatous disease:<\/b> BSA 0.5 m(2) or less: 1.5 mcg\/kg\/dose SUBQ 3 times a week<\/li><li><b>Chronic granulomatous disease:<\/b> BSA greater than 0.5 m(2): 50 mcg\/m(2) SUBQ 3 times a week<\/li><li><b>Osteopetrosis (Severe), Malignant:<\/b> BSA 0.5 m(2) or less: 1.5 mcg\/kg\/dose SUBQ 3 times a week<\/li><li><b>Osteopetrosis (Severe), Malignant:<\/b> BSA greater than 0.5 m(2): 50 mcg\/m(2) SUBQ 3 times a week<\/li><\/ul>"},{"id":"301690-s-1-6","title":"Dose Adjustments","mono":"<b>severe reactions:<\/b> reduce dose by 50% or discontinue therapy until adverse reaction abates"},{"id":"301690-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Chronic granulomatous disease<\/li><li>Osteopetrosis (Severe), Malignant<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Atopic dermatitis<br\/>"}]},"3":{"id":"301690-s-3","title":"Contraindications\/Warnings","sub":[{"id":"301690-s-3-9","title":"Contraindications","mono":"hypersensitivity to interferon-gamma, E. coli derivatives, or any component of the product <br\/>"},{"id":"301690-s-3-10","title":"Precautions","mono":"<ul><li>children less than 1 year of age; the incidence of elevations of transaminases (up to 25-fold) appears to be higher in patients less than 1 year of age compared to older children<\/li><li>pre-existing cardiac conditions including ischemia, congestive heart failure, or arrhythmia; exacerbation may occur<\/li><li>pre-existing myelosuppression; reversible neutropenia and thrombocytopenia have been observed<\/li><li>seizure disorders or compromised central nervous system function; exacerbation may occur<\/li><\/ul>"},{"id":"301690-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Interferon Gamma: C (FDA)<\/li><li>Interferon Gamma: B3 (AUS)<\/li><\/ul>"},{"id":"301690-s-3-12","title":"Breast Feeding","mono":"Interferon Gamma: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"301690-s-4","title":"Drug Interactions","sub":[{"id":"301690-s-4-13","title":"Contraindicated","mono":"<ul>Rotavirus Vaccine, Live (established)<\/ul>"}]},"5":{"id":"301690-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site pain, Rash<\/li><li><b>Gastrointestinal:<\/b>Nausea and vomiting<\/li><li><b>Musculoskeletal:<\/b>Arthralgia, Myalgia<\/li><li><b>Neurologic:<\/b>Headache<\/li><li><b>Other:<\/b>Fatigue, Fever, Influenza-like illness<\/li><\/ul><b>Serious<\/b><br\/><b>Hematologic:<\/b>Leukopenia, Thrombocytopenia<br\/>"},"6":{"id":"301690-s-6","title":"Drug Name Info","sub":{"0":{"id":"301690-s-6-17","title":"US Trade Names","mono":"Actimmune<br\/>"},"2":{"id":"301690-s-6-19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Interferon, Gamma (class)<\/li><\/ul>"},"3":{"id":"301690-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"301690-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"301690-s-7","title":"Mechanism Of Action","mono":"Interferon gamma-1b is a biologic response modifier that is classified as type 2 interferon. Its specific actions include stimulation of the natural killer (NK) cells, improvement of the oxidative metabolism of macrophages, antibody dependent cellular cytotoxicity (ADCC), and the expression of major histocompatibility antigens and Fc receptors.<br\/>"},"8":{"id":"301690-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"301690-s-8-23","title":"Absorption","mono":"<ul><li>IM: time to peak concentration, approximately 4 h<\/li><li>Subcutaneous: time to peak concentration, 7 h<\/li><li>Bioavailability: greater than 89%<\/li><\/ul>"},"3":{"id":"301690-s-8-26","title":"Excretion","mono":"Renal: none <br\/>"},"4":{"id":"301690-s-8-27","title":"Elimination Half Life","mono":"<ul><li>IV: 38 min<\/li><li>IM: 2.9 h<\/li><li>Subcutaneous: 5.9 h<\/li><\/ul>"}}},"9":{"id":"301690-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>avoid excessive or vigorous agitation; do not shake<\/li><li>optimal sites of injection are the right and left deltoid and anterior thigh<\/li><\/ul>"},"10":{"id":"301690-s-10","title":"Monitoring","mono":"<ul><li>reduction in disease progression and frequency of serious infections<\/li><li>CBC with differential; baseline and at 3 month intervals during therapy<\/li><li>blood chemistries and renal function tests; baseline and at 3 month intervals during therapy<\/li><li>hepatic function tests; baseline and at 3 month intervals during therapy; monthly, in pediatrics less than 1 year of age<\/li><li>urinalysis; baseline and at 3 month intervals during therapy<\/li><\/ul>"},"11":{"id":"301690-s-11","title":"How Supplied","mono":"<b>Actimmune<\/b><br\/>Subcutaneous Solution: 2 Million IU\/0.5 ML<br\/>"},"12":{"id":"301690-s-12","title":"Toxicology","sub":[{"id":"301690-s-12-31","title":"Clinical Effects","mono":"<b>INTERFERONS<\/b><br\/>OVERDOSE: Data are limited. Shivers, myalgias, low grade fever and tachycardia have been reported. ADVERSE EFFECTS: \"flu-like\" symptoms (fever, chills, tachycardia, headache, malaise, and myalgias), hypotension, seizures, headache, lethargy, fatigue, elevated liver enzymes, leukopenia, & renal insufficiency; dysrhythmias in patients with underlying heart disease. Vomiting, diarrhea, hyperkalemia, hypocalcemia occur at high doses.<br\/>"},{"id":"301690-s-12-32","title":"Treatment","mono":"<b>INTERFERONS<\/b><br\/><ul><li>Decontamination: Not indicated; broken down in the gut on oral ingestion.<\/li><li>Influenza-like illness: Treat with acetaminophen or non-steroidal anti-inflammatory agents<\/li><li>Hypotensive episode: Transient, usually requires no treatment;  0.9% NaCl 10-20 ml\/kg, dopamine, epinephrine if persistent<\/li><li>Monitoring of patient: CBC, hepatic &amp; renal function; ECG, calcium, potassium if severe overdose.<\/li><\/ul>"},{"id":"301690-s-12-33","title":"Range of Toxicity","mono":"<b>INTERFERONS<\/b><br\/>Single doses greater than 100-200 million units associated with toxicity. <br\/>"}]},"13":{"id":"301690-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause nausea, vomiting, arthralgia, myalgia, headache, fatigue, fever, or influenza-like illness.<\/li><li>Instruct patient to report signs\/symptoms of leukopenia or thrombocytopenia.<\/li><li>Patients with a history of cardiac disease or seizures should report signs\/symptoms of disease exacerbation during drug therapy.<\/li><li>Teach patient proper technique and placement of injections.<\/li><li>Advise patient to rotate injection sites.<\/li><\/ul>"}}}